Differential hRad17 Expression by Histologic Subtype of Ovarian Cancer

DSpace/Manakin Repository

Differential hRad17 Expression by Histologic Subtype of Ovarian Cancer

Citable link to this page


Title: Differential hRad17 Expression by Histologic Subtype of Ovarian Cancer
Author: Young, Jennifer L; Koon, E Colin; Kwong, Joseph; Mok, Samuel C; Welch, William Robert; Muto, Michael George; Berkowitz, Ross Stuart

Note: Order does not necessarily reflect citation order of authors.

Citation: Young, Jennifer L, E Colin Koon, Joseph Kwong, William R Welch, Michael G Muto, Ross S Berkowitz, and Samuel C Mok. 2011. Differential hRad17 expression by histologic subtype of ovarian cancer. Journal of Ovarian Research 4:6.
Full Text & Related Files:
Abstract: Background: In the search for unique ovarian cancer biomarkers, ovarian specific cDNA microarray analysis identified hRad17, a cell cycle checkpoint protein, as over-expressed in ovarian cancer. The aim of this study was to validate this expression. Methods: Immunohistochemistry was performed on 72 serous, 19 endometrioid, 10 clear cell, and 6 mucinous ovarian cancers, 9 benign ovarian tumors, and 6 normal ovarian tissue sections using an anti-hRad17 antibody. Western blot analysis and quantitative PCR were performed using cell lysates and total RNA prepared from 17 ovarian cancer cell lines and 6 normal ovarian epithelial cell cultures (HOSE). Results: Antibody staining confirmed upregulation of hRad17 in 49.5% of ovarian cancer cases. Immunohistochemistry demonstrated that only 42% of serous and 47% of endometrioid subtypes showed overexpression compared to 80% of clear cell and 100% of mucinous cancers. Western blot confirmed overexpression of hRad17 in cancer cell lines compared to HOSE. Quantitative PCR demonstrated an upregulation of hRad17 RNA by 1.5-7 fold. hRad17 RNA expression differed by subtype. Conclusions: hRad17 is over-expressed in ovarian cancer. This over-expression varies by subtype suggesting a role in the pathogenesis of these types. Functional studies are needed to determine the potential role of this protein in ovarian cancer.
Published Version: doi://10.1186/1757-2215-4-6
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077316/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:5978750
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search